View Older Stories View More Recent Stories
-
Needham: 'we believe that the Section 232 investigation creates a new overhang for the already beleaguered medical device sector'
-
Rothschild Redburn Starts Stryker (SYK) at Neutral
-
This MedTech stock is 'a strong buy under $500': Bernstein
-
Stryker (SYK) Declares $0.84 Quarterly Dividend; 0.9% Yield
-
Stryker (SYK) PT Raised to $415 at Truist After 2Q Beat and Raise
-
Citizens JMP Reiterates Market Perform Rating on Stryker (SYK)
-
Stryker (SYK) PT Raised to $448 at Needham
-
Stryker (SYK) Tops Q2 EPS by 6c; offers guidance
-
Stryker (SYK) Tops Q2 EPS by 6c, raises guidance
-
Stryker's Inari launches new InThrill thrombectomy system for small vessels
-
Stryker (SYK) receives FDA clearance for Incompass Total Ankle System
-
Barclays on Stryker (SYK): 'Under-appreciated Double-Digit Growth Engine'
-
Stryker (SYK) recieves FDA clearance for OptaBlate BVN
-
Stryker (SYK) Declares $0.84 Quarterly Dividend; 0.9% Yield
-
Stryker (SYK) PT Raised to $421 at UBS
-
Stryker (SYK) PT Lowered to $390 at Evercore ISI
-
Stryker (SYK) Tops Q1 EPS by 13c; offers guidance
-
TD Cowen Reiterates Buy Rating on Stryker (SYK), Citing 'Strong Underlying Momentum'
-
RBC Capital Assesses U.S. Tariff Impact Across Industries
-
Evercore Adds 7 Names to Tactical Outperform List
-
Stryker (SYK) completes sale of U.S. spinal implants business
-
Stryker (SYK) announces intention to nominate Manny Maceda to board of directors
-
Needham Reiterates Buy Rating on Stryker (SYK)
-
RBC Capital on Stryker (SYK): 'Positive Takeaways from CEO Meeting at AAOS'
-
Piper Sandler: 'Stryker (SYK) Expected To Benefit From Strong Market Growth'
-
RBC Capital: 'Opportunities Across MedTech Stocks'
-
Stryker (SYK) launches Steri-Shield 8 personal protection system
-
Stryker (SYK) launches Sync Badge
-
Citi Starts Stryker (SYK) at Buy
-
Kadant (KAI) to Join S&P SmallCap 600
-
Stryker (SYK) Announces Retirement of Allan Golston from Board
-
Stryker (SYK) Declares $0.84 Quarterly Dividend; 0.9% Yield
-
Stryker (SYK) PT Raised to $413 at Truist Securities
-
Stryker (SYK) PT Raised to $440 at Stifel
-
RBC Capital on Stryker (SYK): 'We are Bullish on SYK's Durability of Growth'; PT Raised to $435
-
Stryker (SYK) PT Raised to $416 at BTIG
-
Stryker (SYK) PT Raised to $440 at Bernstein After a 'Strong Finish'
-
Stryker (SYK) to Sell U.S. spinal implants business, announces plans to sell related international business
-
Stryker (SYK) Announces CFO Change
-
Stryker (SYK) Tops Q4 EPS by 14c; offers guidance
-
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Inari Medical, Inc. (NARI)
-
Stryker (SYK) commences tender offer for all outstanding shares of common stock of Inari Medical
-
BTIG Downgrades Inari Medical Inc. (NARI) to Neutral
-
TD Cowen on Stryker (SYK): 'We Are Positive on SYK's Plan to Acquire NARI'
-
BofA Securities Reiterates Buy Rating on Stryker (SYK)
-
Inari Medical Inc. (NARI) PT Raised to $80 at Piper Sandler Following Acquisition Agreement with Stryker (SYK)
-
Evercore ISI Reiterates Outperform Rating on Stryker (SYK)
-
Stifel on Inari Medical Inc. (NARI): 'Quick Thoughts on the Deal and PEN Implications'
-
After-hours movers: Ulta Beauty, Inari Medical, Meta Platforms and more
-
Stryker (SYK) to acquire Inari Medical (NARI) for $80 Per Share, $4.9 Billion

